Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IMPROVEd Timing On Vytorin Outcomes Data?

This article was originally published in The Pink Sheet Daily

Executive Summary

Full results from the massive study will be delayed a year, but an earlier interim analysis could help resolve questions about the safety and efficacy of Merck's cholesterol drug.

You may also be interested in...

FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming

SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.

Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive

However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.

Vytorin Re-Endorsed By FDA Despite Lack Of Impact On Carotid Artery Thickness

Agency offers three possible explanations for why a reduction in LDL failed to translate into a drop in cIMT.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts